Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript from Zydus Wellness Limited's Q3 and 9 months FY '24 earnings call. The company has substantially reduced its debt over the years and is now practically at a debt-free status (Page 15). The management emphasized a calibrated approach to expansion and cost management but did not indicate plans for raising new funds via debt or equity. The focus is on driving growth through operational improvements, margin enhancements, product launches, and distribution expansion rather than exte

Future growth expectations in sales/revenue/volumes?

Company expects growth to return starting Q4 FY24, with FY25 targeted to achieve normal double-digit growth. Personal care brands (e.g., Everyuth) show strong growth potential, driven by scrub and peel-off categories. Distribution expansion planned to increase availability from 2.9 million to 3.5 million outlets over the next three years, supporting growth. Complan aims for volume growth aided by 16% household penetration increase, with focused marketing on superior protein benefits. Sweetener portfolio growth driven mainly by Sugar Free Green (stevia-based), expanding over 11-12 quart

Future growth expectations in earnings/operating earnings/profits/EPS?

Earnings growth to improve driven by gross margin expansion and operating leverage if demand improves (Page 15). EBITDA margins targeted to return to 17-18% over next two years with margin improvement initiatives (Pages 13-15). Gross margins expected to further improve in FY '24 due to commodity price and milk price stabilization (Page 8). Operating profit margin likely to improve from current levels as costs reduce and demand stabilizes (Page 15). Volume growth expected to normalize and return to double-digit in FY '25 after early signs of demand improvement from Q4 FY '24 (Pages 6, 16). Mana

Zydus WellnessQ3 FY24Food Products

Zydus Wellness Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹493P/E: 74.8Market Cap: ₹16.6K CrSector: Food Products

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Company expects growth to return starting Q4 FY24, with FY25 targeted to achieve normal double-digit growth.
Personal care brands (e.g., Everyuth) show strong growth potential, driven by scrub and peel-off categories.
Distribution expansion planned to increase availability from 2.9 million to 3.5 million outlets over the next three years, supporting growth.
Complan aims for volume growth aided by 16% household penetration increase, with focused marketing on superior protein benefits.
Sweetener portfolio growth driven mainly by Sugar Free Green (stevia-based), expanding over 11-12 quarters, with Sugar Lite expected to resume post-March after litigation resolution.
International business growth challenged by macroeconomic issues in Nigeria but progressing well in Bangladesh and Middle East, with double-digit growth over nine months.
Gross margins expected to improve due to stabilized commodity prices and calibrated price increases, supporting profitability and volume growth.

Margin guidance

Category 2

Earnings growth to improve driven by gross margin expansion and operating leverage if demand improves (Page 15).
EBITDA margins targeted to return to 17-18% over next two years with margin improvement initiatives (Pages 13-15).
Gross margins expected to further improve in FY '24 due to commodity price and milk price stabilization (Page 8).
Operating profit margin likely to improve from current levels as costs reduce and demand stabilizes (Page 15).
Volume growth expected to normalize and return to double-digit in FY '25 after early signs of demand improvement from Q4 FY '24 (Pages 6, 16).
Management expects overall positive growth momentum in 2024 with better demand and cost control (Page 16).
Price increases will be calibrated to protect margins but not uniform across all brands (Page 12).

See what Zydus Wellness management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript from Zydus Wellness Limited's Q3 and 9 months FY '24 earnings call.
The company has substantially reduced its debt over the years and is now practically at a debt-free status (Page 15).
The management emphasized a calibrated approach to expansion and cost management but did not indicate plans for raising new funds via debt or equity.
The focus is on driving growth through operational improvements, margin enhancements, product launches, and distribution expansion rather than external fundraising.

Order book

The provided transcript of Zydus Wellness Limited's Q3 FY24 earnings call does not explicitly mention any details regarding the current or expected order book or pending orders. The discussion primarily focuses on: - Brand performance (Immunovolt, Sugar Free variants, Sugar Lite) - Market demand and growth drivers - Distribution expansion plans - Margin improvement strategies - Challenges in specific markets and segments - Litigation impact on Sugar Lite sales - International market performance and growth plans No specific quantitative or qualitative information about order books or pending orders has been disclosed in the transcript. For detailed or updated information on order books or pending orders, contacting the company's Investor Relations directly is recommended.

See what Zydus Wellness management said on order book — free account, 30 seconds.

Capex plans

Yes

- Zydus Wellness is actively working on distribution expansion, aiming to grow direct coverage from 6-6.5 lakh outlets to 3.5 million outlets in general trade over the next three years. - They plan to add 50,000 to 1 lakh more outlets post the summer season as part of this expansion. - The company is launching 3 to 4 reasonably large new products over the next 2-3 years, focusing on innovation and capability to drive growth. - Investments are ongoing in international markets, notably in Bangladesh through a new subsidiary and product launches in Middle East (e.g., Sugar Free D'lite). - Distribution and channel-led initiatives are being undertaken for key categories like face wash and body lotion. - Focus remains on calibrated investments balancing cost management with expansion to enhance penetration and reach. No explicit mention of large one-time capex or strategic acquisitions was noted in the provided transcript.

Track Zydus Wellness — get its next earnings analysis in your feed

How does Zydus Wellness rank vs peers in Food Products?

Pro feature

ThisZydus Wellness

Rev 3Mar 2

See where Zydus Wellness sits in Food ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Zydus Wellness rank in Food Products?

Compare Zydus Wellness against every Food Products company (Q3 FY24) on revenue, margins and earnings-call signals.

View Food Products leaderboard →

What Zydus Wellness's management said in earlier quarters

Others in Food Products this season

Sheetal Cool Products Ltd (Q1 FY27)
Revenue from Operations for FY26: ₹366.0 Crores, up 13.9% YoY from ₹321.3 Crores in FY25 (Page 29, 5). Key investor presentation takeaways from Sheetal Cool Pro
Mukka Proteins Ltd (Q4 FY26)
Q4 FY26 Revenue from Operations:** ₹381.6 Cr . Key concall takeaways from Mukka Proteins Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Mukka Proteins Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹489.7 crore . Key concall takeaways from Mukka Proteins Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
Shri Ahimsa Naturals Ltd (Q4 FY26)
Revenue figures (₹ in Crs) for FY: . Key concall takeaways from Shri Ahimsa Naturals Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Nestle India vs Britannia Inds.vs Hatsun Agro Product Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →